Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.8100 (0.29%) ($6.6800 - $6.9600) on Mon. Apr. 8, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5% (three month average) | RSI | 19 | Latest Price | $6.8100(0.29%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.3% a day on average for past five trading days. | Weekly Trend | ADMS declines -5.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) EWI(9%) ONLN(9%) XBI(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.5% in a week (0% probabilities). UUP(-10%) BNDX(-10%) GLD(-8%) GDX(-8%) GDXJ(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.5% (StdDev 5%) | Hourly BBV | 0 () | Intraday Trend | 0.7% | | | |
|
1 - 5 Day Possible Target | $-3.24(-147.58%) | Resistance Level | $7.4 | 5 Day Moving Average | $6.89(-1.16%) | 10 Day Moving Average | $7.06(-3.54%) | 20 Day Moving Average | $7.4(-7.97%) | To recent high | -44% | To recent low | 0.3% | Market Cap | $193m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |